RQM+ recently announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical, and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics.

“As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer proprietary testing services for extractables and leachables, which gives our customers the fastest path to regulatory approvals,” said CEO Margaret Keegan. “We are relentlessly focused on being the best at every service we provide to MedTech manufacturers. Jordi’s world-leading testing services will help us maintain our uncompromising quality standards at every stage as we grow into a one-stop-shop to expedite patient access to life-improving technologies.”

Through innovative new processes, Jordi Labs provides chemical characterization and complex product deformulation as well as contaminant and failure investigations to MedTech manufacturers. Their team of PhD analytical chemists uses its proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements. Jordi’s publications based on their multi-detector approach are frequently cited by both regulators and industry.

“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators globally,” said Mark Jordi, President of Jordi Labs. “Joining RQM+ will enable me to focus on what I love – developing groundbreaking technology that ensures patient safety by setting new standards for extractables and leachables testing.”

Kirkland and Ellis LLP served as legal advisor to Linden. Harris Williams represented Jordi Labs.

RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. We provide comprehensive regulatory, quality, clinical and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics. With more former FDA, MHRA and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. RQM+ currently works for eight of the top 10 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 45 healthcare companies encompassing over 250 total transactions. The firm has raised over $6.5 billion in limited partner commitments since inception. For more information, visit www.lindenllc.com.